New therapeutic approaches to mendelian disorders.

@article{Dietz2010NewTA,
  title={New therapeutic approaches to mendelian disorders.},
  author={Harry C. Dietz},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 9},
  pages={
          852-63
        }
}
  • H. Dietz
  • Published 25 August 2010
  • Biology
  • The New England journal of medicine
Thanks to the power of a method to identify etiologic mutations (and hence “causative” genes) in mendelian disease, the molecular mechanisms that give rise to many such diseases are now known. This knowledge has fueled new therapeutic approaches, which are reviewed in this article, the third in the Genomic Medicine series. 
View on PubMed
commed.vcu.edu
87 Citations
Highly Influential Citations
1
Background Citations
31
Methods Citations
1

Figures from this paper

87 Citations

Citation Type

Citation Type

Cystic fibrosis genetics: from molecular understanding to clinical application
  • G. Cutting
  • Biology, Medicine
    Nature Reviews Genetics
  • 2015
TLDR
Recent progress in elucidating disease mechanism and causes of phenotypic variation, as well as in the development of treatments, demonstrates that genetics continues to play an important part in cystic fibrosis research 25 years after the discovery of the disease-causing gene.
Expanding rare disease drug trials based on shared molecular etiology
Current clinical trial approaches in rare disease test one drug on one indication defined by a clinical phenotype. For targeted drugs, grouping patients by molecular etiology would make much more…
Rare Diseases and Orphan Products: Accelerating Research and Development
TLDR
The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.
The expanding role of epigenetics
TLDR
Epigenetics in molecular cardiology is the focus of this review, and all three basic levels of biological information, DNA, RNA and proteins, are being revisited, and exciting new discoveries are promising to change the way the authors view and combat heart disease.
Gene Therapy for Hereditary Hearing Loss
TLDR
Some of the recent advances toward the goal of developing gene therapy as a treatment for hereditary hearing loss in humans are summarized.
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies
TLDR
Current strategies being pursued for the development of clinical gene therapy for dyslipidemias that cannot effectively be treated with existing drugs are summarized.
Genetics of Human Cardiovascular Disease
Charting a course for genomic medicine from base pairs to bedside
TLDR
A vision for the future of genomics research is articulated and the path towards an era of genomic medicine is described, as advances in genomics are harnessed to obtain robust foundational knowledge about the structure and function of the human genome.
Pathogenetics of Disease
Advancing drug discovery using the power of the human genome
TLDR
The history of human genetics in the context of accelerating the discovery of therapies is reviewed, examples of how human genetics evidence supports successful drug targets are presented, and how polygenic risk scores could be beneficial in various clinical settings.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Randomized, controlled trial of miglustat in Gaucher's disease type 3
To evaluate the efficacy and safety of miglustat, concomitant with enzyme replacement therapy (ERT), in patients with Gaucher's disease type 3 (GD3).
Therapy of Marfan syndrome.
TLDR
TGFbeta antagonists have shown great success in improving or preventing several manifestations of Marfan syndrome in these mice, including aortic aneurysm, and highlight the potential for development of targeted therapies based on discovery of disease genes and interrogation of pathogenesis in murine models.
Treatment of Gaucher disease with an enzyme inhibitor
  • N. Radin
  • Biology
    Glycoconjugate Journal
  • 2004
TLDR
The hypothesis is offered predicting that Caucher patients could be treated with a drug that slows the synthesis of glucosylceramide, the lipid that accumulates in this disorder, and 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), a designer inhibitor that resembles the synthase's substrate and product is found to be effective.
Review of miglustat for clinical management in Gaucher disease type 1
  • C. Ficicioglu
  • Medicine, Biology
    Therapeutics and clinical risk management
  • 2008
TLDR
The results of clinical studies and use of miglustat as a therapeutic agent in patients with type I Gaucher disease are discussed.
Translation of the Philadelphia chromosome into therapy for CML.
TLDR
The understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance, which will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.
Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis.
  • D. Sleat, I. Sohar, R. Gin, P. Lobel
  • Biology, Medicine
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2001
TLDR
The results suggest that pharmacological suppression of nonsense mutations by aminoglycosides or functionally similar pharmaceuticals may have therapeutic potential in LINCL.
An unexpected twist for autophagy in Crohn's disease
TLDR
Autophagy is important in regulating the secretory function of Paneth cells and the production of inflammatory cytokines in the intestine in mice deficient in the autophagy-related gene product Atg16L1.
Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome
TLDR
Evidence of mutations in lamin A (LMNA) as the cause of Hutchinson–Gilford progeria syndrome is presented, and the discovery of the molecular basis of this disease may shed light on the general phenomenon of human ageing.
PTC124 targets genetic disorders caused by nonsense mutations
TLDR
The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options.
Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations
TLDR
In the mdx mouse, where muscular dystrophy is due to a nonsense mutation in the dystrophin gene, gentamicin suppressed truncation of the protein and ameliorated the phenotype, and full‐length dyStrophin was not detected in pre‐ and post‐treatment muscle biopsies.
...
1
2
3
4
5
...